A magnetic resonance imaging apparatus according to an embodiment includes: a coil configured to receive a magnetic resonance signal emitted from a subject due to influence of a radio frequency magnetic field; and processing circuitry. The processing circuitry is configured to detect at least one tissue from among a femoral head, the pelvis, an articular labrum, the pubic symphysis, the urethra, and the apex of the prostate of the subject, from a locator image based on the magnetic resonance signal and corresponding to a range including the prostate of the subject. The processing circuitry is configured to determine a region to be imaged of the prostate of the subject, on the basis of the detected tissue.

There is provided a computer implemented method of automatic segmentation of three dimensional (3D) anatomical region of interest(s) (ROI) that includes predefined anatomical structure(s) of a target individual, comprising: receiving 3D images of a target individual, each including the predefined anatomical structure(s), each 3D image is based on a different respective imaging modality. In one implementation, each respective 3D image is inputted into a respective processing component of a multi-modal neural network, wherein each processing component independently computes a respective intermediate, and the intermediate outputs are inputted into a common last convolutional layer(s) for computing the indication of segmented 3D ROI(s). In another implementation, each respective 3D image is inputted into a respective encoding-contracting component a multi-modal neural network, wherein each encoding-contracting component independently computes a respective intermediate output. The intermediate outputs are inputted into a single common decoding-expanding component for computing the indication of segmented 3D ROI(s).

A method for calibration of the MRμTexture method is presented wherein a plurality of model datasets representing a continuum of structures with a continuum of biomarker values is generated by morphing data of a 2D structure or 3D structure of a first known disease state to a 2D structure or a 3D structure of a second known disease state. MRμTexture is applied in silico to extract a simulation data set of texture prevalence for a selected one of a plurality of intermediate morphed conditions corresponding to the plurality of model datasets.

There is provided a computer implemented method of automatic segmentation of three dimensional (3D) anatomical region of interest(s) (ROI) that includes predefined anatomical structure(s) of a target individual, comprising: receiving 3D images of a target individual, each including the predefined anatomical structure(s), each 3D image is based on a different respective imaging modality. In one implementation, each respective 3D image is inputted into a respective processing component of a multi-modal neural network, wherein each processing component independently computes a respective intermediate, and the intermediate outputs are inputted into a common last convolutional layer(s) for computing the indication of segmented 3D ROI(s). In another implementation, each respective 3D image is inputted into a respective encoding-contracting component a multi-modal neural network, wherein each encoding-contracting component independently computes a respective intermediate output. The intermediate outputs are inputted into a single common decoding-expanding component for computing the indication of segmented 3D ROI(s).

In a method for generating a surrogate marker based on medical image data mapping an image region, the medical image data is detected using a first interface, a first subregion of the image region is selected by segmenting a first structure included in the image region, a first property of the first subregion is extracted, the surrogate marker is determined based on the first property, and the surrogate marker is provided using a second interface.

The present disclosure relates to a method for detecting a prostate cancer related biomarker, including contacting the diluted sample with a modulating agent selected from a group consisting of sodium; 3-hydroxy-4-[(2-hydroxynaphthalen-1-yl)diazenyl]naphthalene-1-sulfonate, sodium; 3-hydroxy-4-[(1-hydroxynaphthalen-2-yl)diazenyl]-7-nitronaphthalene-1-sulfonate, triisopropylsilane, and iron(III) chloride, and a luminescent label to obtain a measurement sample. Then, the measurement sample is incubated for a period of time and excited thereafter. Time-resolved luminescence signal of the label in the measurement sample is measured, leading to an increased likelihood of prostate cancer of the human subject if the luminescence signal is at least 50% higher than for a control sample from a human subject without prostate cancer.

A disposable medical device assembly for measuring a physiological parameter in a urinary or gastrointestinal tract of a mammal being is disclosed, comprising a probe, such as a catheter, for insertion into a bodily opening of the mammal being. The probe comprises at least one sensor, such as a pressure sensor. The medical device further comprises an energy source, in the form of a biofuel cell, connected to the at least one sensor.

Systems and methods are provided herein that generally involve measuring a prostate or other object. In some embodiments, a finger clip having a roller ring or wheel rotatably mounted thereto is disposed within an inflatable membrane. The roller ring can include a measurement pattern positioned opposite to optical fibers configured to receive light reflected from the measurement pattern. A user can put on the finger clip, position the membrane in proximity to a rectal wall overlying a prostate, and inflate the membrane. As the user slides their finger across the inside of the membrane, which is pressed against the rectal wall, the roller ring can rotate with respect to the fibers such that the fibers move relative to the measurement pattern. A controller can sense light reflected through the fibers from the reference pattern and calculate or estimate various attributes of the prostate based on the reflected light.

In some aspects, the present disclosure provides gadolinium based sensors which may be used to image zinc ions in vivo. In some embodiments, the compounds show appropriate reactivity with zinc ions while maintaining high relaxivity to achieve improved background relative to other sensors.

The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.